<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642445</url>
  </required_header>
  <id_info>
    <org_study_id>HenanICE201502</org_study_id>
    <nct_id>NCT02642445</nct_id>
  </id_info>
  <brief_title>Renal Sympathetic Denervation From The Adventitia on Hypertension</brief_title>
  <acronym>RSDAH</acronym>
  <official_title>Efficacy and Safety of Renal Sympathetic Denervation From The Adventitia on Hypertension in Patients With Primary Aldosteronism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Institute of Cardiovascular Epidemiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Institute of Cardiovascular Epidemiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal sympathetic denervation from the intima of renal arteries has become an important&#xD;
      method for the treatment of resistant hypertension, but renal sympathetic nerve are mainly&#xD;
      located in the adventitia, and there is no report about renal sympathetic denervation from&#xD;
      the renal adventitia. Primary aldosteronism is an important factor of secondary hypertension,&#xD;
      tumor aldosterone in unilateral adrenal can increase the concentration of plasma aldosterone,&#xD;
      in some patients blood pressure control is still not desirable after resection of tumor&#xD;
      aldosterone. This study intends to conduct renal sympathetic denervation ablation from the&#xD;
      adventitia to observe its efficacy and safety on blood pressure of patients with primary&#xD;
      aldosterone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Renal sympathetic denervation from the intima of renal arteries has become an important&#xD;
      method for the treatment of resistant hypertension, but renal sympathetic nerve are mainly&#xD;
      located in the adventitia, and there is no report about renal sympathetic denervation from&#xD;
      the renal adventitia. Primary aldosteronism is an important factor of secondary hypertension,&#xD;
      tumor aldosterone in unilateral adrenal can increase the concentration of plasma aldosterone,&#xD;
      in some patients blood pressure control is still not desirable after resection of tumor&#xD;
      aldosterone.&#xD;
&#xD;
      This study intends to conduct renal sympathetic denervation ablation（RDN）from the adventitia&#xD;
      to observe its efficacy and safety on blood pressure of patients with primary aldosterone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Systolic Blood Pressure at 6 months,12 months, 18 months</measure>
    <time_frame>at 6 months,12 months,18 months</time_frame>
    <description>The Change of Systolic Blood Pressure from Baseline to 6 months,12 months, 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Renin at 6 months,12 months, 18 months</measure>
    <time_frame>at 6 months,12 months,18 months</time_frame>
    <description>The Change of Renin from Baseline to 6 months,12 months, 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline aldosterone at 6 months,12 months, 18 months</measure>
    <time_frame>at 6 months,12 months,18 months</time_frame>
    <description>The Change of aldosterone from Baseline to 6 months,12 months, 18 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Primary Aldosteronism Due to Aldosterone Producing Adenoma</condition>
  <arm_group>
    <arm_group_label>Renal Sympathetic Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal sympathetic Denervation are conducted from the adventitia of renal artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Renal Sympathetic Denervation are not conducted in control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Sympathetic Denervation</intervention_name>
    <description>We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia</description>
    <arm_group_label>Renal Sympathetic Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. . Renal artery diameter ≥4 mm and Length ≥20 mm;&#xD;
&#xD;
          2. . 18 years old ≤ age ≤ 70 years old;&#xD;
&#xD;
          3. . Specific diagnosis of adrenal adenoma and primary aldosteronism before the patients&#xD;
             are enrolled in the study;&#xD;
&#xD;
          4. . Clinic systolic blood pressure≥160 mmHg and/or diastolic blood pressure≥100 mmHg&#xD;
             (patients with type 2 diabetes: clinic systolic blood pressure≥150 mmHg and/or&#xD;
             diastolic blood pressure≥95 mmHg) .&#xD;
&#xD;
          5. . 24 hours ambulatory blood pressure (SBP/DBP)≥140 and/or 90 mmHg;&#xD;
&#xD;
          6. . Estimated GFR (eGFR)≥45 ml/min / 1.73 m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. . Renal artery abnormalities include: either side renal arterial blood flow mechanics&#xD;
             or anatomical obvious stenosis (≥50% ); Underwent renal artery balloon angioplasty or&#xD;
             inserting a stent; Renal artery anatomy apparently is unusual to insert catheter;&#xD;
&#xD;
          2. . Cardiovascular instability includes: myocardial infarction in six months, unstable&#xD;
             angina or cerebrovascular disease; Thrombus or unstable plaques in the arteries with&#xD;
             extensive atherosclerosis; Hemodynamic apparently change in patients with heart valve&#xD;
             disease;&#xD;
&#xD;
          3. . The patients with typeⅠdiabetes;&#xD;
&#xD;
          4. . Other serious organic disease;&#xD;
&#xD;
          5. . Participated in other clinical research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ChuanYu Gao, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Institute of Cardiovascular Epidemiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dayi Hu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Institute of Cardiovascular Epidemiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhengzhou university People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 19, 2015</study_first_submitted>
  <study_first_submitted_qc>December 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Institute of Cardiovascular Epidemiology</investigator_affiliation>
    <investigator_full_name>Chuanyu Gao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Renal sympathetic denervation;hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

